Peer-influenced content. Sources you trust. No registration required. This is HCN.

The Epoch TimesCompound Found in Broccoli Could Help Dissolve Blood Clots and Prevent Stroke

Exploring Sulforaphane’s Role in Stroke Prevention and Treatment

Recent research from the Heart Research Institute (HRI) in Australia highlights the potential of sulforaphane, a compound found in broccoli and other cruciferous vegetables, in improving stroke treatment outcomes and offering a preventative approach. This study lookes into the natural chemical’s interaction with conventional stroke medication, presenting a new angle on dietary influence in medical conditions.

Key Points:

  • Researchers at the Heart Research Institute (HRI) have discovered that sulforaphane, a compound in broccoli, might enhance the efficacy of stroke treatments.
  • Sulforaphane has been observed to improve the action of tissue plasminogen activator (tPA), the primary treatment for acute ischemic stroke, which constitutes 87% of all stroke cases.
  • The substance was identified during a three-year study aimed at finding natural products that could prevent blood clots, particularly in the brain.
  • Sulforaphane’s benefits extend beyond clot prevention; it does not increase the risk of bleeding, a common side effect in current stroke treatments.
  • Preclinical trials have shown that combining sulforaphane with tPA increases the treatment’s success rate to 60% without causing bleeding.
  • The compound is activated in cruciferous vegetables only when they are cut or chewed, initiating a chemical reaction that produces sulforaphane.
  • Beyond its potential in stroke treatment, sulforaphane is recognized for its antioxidant, anti-inflammatory, and anti-cancer properties.
  • The next steps involve securing funding for human clinical trials with the aim of developing a new treatment that leverages sulforaphane’s properties within five years.

“We are looking for clues in nature to find this magic anti-clotting drug which can work where it’s needed but also still allow patients to have antithrombotic treatments.”
– Xuyu Liu, lead researcher

More on Stroke

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form